Neuphoria Therapeutics (NEUP) Non Operating Income (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Non Operating Income for 4 consecutive years, with $671793.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non Operating Income rose 184.37% year-over-year to $671793.0 in Q1 2026; TTM through Mar 2026 was -$1.0 million, a 116.37% decrease from a year earlier, with the FY2025 full-year figure at $291093.0, down 87.41% from the prior year.
• Non Operating Income was $671793.0 for Q1 2026 at Neuphoria Therapeutics, down from $5.9 million in the prior quarter.
• Over five years, Non Operating Income peaked at $5.9 million in Q4 2025 and troughed at -$4.3 million in Q3 2025.
• A 4-year average of $443389.0 and a median of -$36356.0 in 2023 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income surged 6717.58% in 2024 and slumped 263.02% in 2025, its largest moves.
• Over 4 years, Non Operating Income stood at -$36356.0 in 2023, then surged by 4973.39% to $1.8 million in 2024, then surged by 232.44% to $5.9 million in 2025, then plunged by 88.59% to $671793.0 in 2026.
• The last three Non Operating Income figures came in at $671793.0 (Q1 2026), $5.9 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.